Elucidation of a new activation regulation mechanism for the anti-viral factor interferon

Research Press Release | October 22, 2013

Press Release
Key Points – Jun activation domain-binding protein 1 (JAB1), which is responsible for proteolytic system, has been identified as a new binding partner for tyrosine kinase 2 (TYK2), a molecule involved in interferon (IFN) signal transduction.

– When a low-molecular-weight compound that inhibits the proteolytic system molecular group regulated by JAB1 was liberated, IFN receptor protein levels increased (indicating decreased degradation), and activation of downstream signal transduction and increased anti-viral activity / anti-proliferative activity due to IFN stimulation were observed.

– JAB1 and its associated proteolytic system have the potential as new targets for the development of anti-viral and anti-cancer agents.

Overview Cells in vivo produce interferon (IFN) and other cytokines, which are humoral proteins, when they are invaded by viruses or other pathogens as well as in response to the proliferation of tumor cells. IFN is an anti-viral factor that not only inhibits viral proliferation and suppresses tumor cell proliferation, but also acts to regulate the immune system and inflammation, and is a particularly important molecule in the maintenance of bodily homeostasis. IFN is already widely used in clinical practice as an anti-viral and anti-cancer agent.

When cells are stimulated by IFN, its effect is limited by the degradation of IFN receptors. In this study, we discovered that a protein called JAB1, which regulates the proteolytic system, inhibits IFN receptor degradation. When a low-molecular-weight compound that inhibits the proteolytic system molecules regulated by JAB1 was liberated, IFN receptor protein levels increased (indicating decreased degradation), and activation of downstream signal transduction and increased anti-viral activity and anti-proliferative activity due to IFN stimulation were observed. The development of new drugs targeting JAB1 protein and its associated proteolytic system have the potential of being artificially manipulated and elevating the treatment results.

Inquiries

Ryuta Muromoto , Asst. Professor, Faculty of Pharmaceutical Sciences, Hokkaido University

TEL: +81-11-706-3245

FAX:+81-11-706-4990

e-mail: muro@pharm.hokudai.ac.jp

Japanese

Link

http://www.hokudai.ac.jp/news/131009_pr_pharm.pdf
Publications Journal of Biological Chemistry (2013.9.16)

LATEST NEWS

University News | December 01, 2017
HU Ambassador wins the 2017 Volvo Environmental Prize
University News | November 13, 2017
Dinner meeting with Indonesian alumni
Student Awards | November 10, 2017
Student Awards: Graduate School of Medicine
University News | November 10, 2017
The 4th Joint Working Group 2017 Indonesia-Japan
University News | November 10, 2017
Applications for Fall 2018: Integrated Science Program (ISP)

ARCHIVES

CONNECT WITH US

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn

BACK TO TOP